# Heme Iron (Proferrin / Polypeptide Heme) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Clinical studies confirm 3-5x superior bioavailability over ferrous sulfate with minimal gastrointestinal side effects.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **82/100**
- **Evidence Quality Tier**: **bronze**
- **Human Clinical Evidence Strength**: 70/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
HCP-1 receptor-mediated endocytosis of intact porphyrin ring

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 10 mg
- **Recommended Timing**: Morning
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: energy, endurance

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Hemochromatosis / Iron overload disorders
- **Safety Profile**: High - Monitor ferritin levels periodically to avoid iron overload.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Heme Iron Polypeptide vs Ferrous Sulfate for Anemia Correction** [PMID: 21808160]
   - Link: https://pubmed.ncbi.nlm.nih.gov/21808160/
2. **Iron Status and Aerobic Capacity in Active Cohorts** [PMID: 24813589]
   - Link: https://pubmed.ncbi.nlm.nih.gov/24813589/
3. **Heme Iron Polypeptide Corrects Iron Deficiency Anemia in Chronic Kidney Disease and Elderly Adults with Minimal Gastrointestinal Toxicity** [PMID: 14655193]
   - Link: https://pubmed.ncbi.nlm.nih.gov/14655193/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Heme Iron (Proferrin / Polypeptide Heme) on LongevityReviews](https://longevityreviews.org/modalities/heme-iron)
- **Last Evidence Calibration**: 2026-08-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.